JBM (Healthcare) Inkomsten in het verleden
Verleden criteriumcontroles 5/6
JBM (Healthcare) has been growing earnings at an average annual rate of 32.3%, while the Pharmaceuticals industry saw earnings growing at 5.7% annually. Revenues have been growing at an average rate of 14.5% per year. JBM (Healthcare)'s return on equity is 13.4%, and it has net margins of 20.1%.
Belangrijke informatie
32.3%
Groei van de winst
48.3%
Groei van de winst per aandeel
| Pharmaceuticals Groei van de industrie | 5.6% |
| Inkomstengroei | 14.5% |
| Rendement op eigen vermogen | 13.4% |
| Nettomarge | 20.1% |
| Volgende winstupdate | 19 Nov 2024 |
Recente prestatie-updates uit het verleden
Recent updates
JBM (Healthcare)'s (HKG:2161) Earnings Are Weaker Than They Seem
Dec 20
Here's Why JBM (Healthcare) (HKG:2161) Has Caught The Eye Of Investors
Nov 01JBM (Healthcare) Limited's (HKG:2161) Shares May Have Run Too Fast Too Soon
Jul 29Some Investors May Be Willing To Look Past JBM (Healthcare)'s (HKG:2161) Soft Earnings
Aug 03Estimating The Fair Value Of JBM (Healthcare) Limited (HKG:2161)
Jul 28Opbrengsten en kosten
Hoe JBM (Healthcare) geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 31 Mar 24 | 648 | 130 | 180 | 0 |
| 31 Dec 23 | 629 | 114 | 175 | 0 |
| 30 Sep 23 | 610 | 98 | 170 | 0 |
| 30 Jun 23 | 565 | 78 | 154 | 0 |
| 31 Mar 23 | 520 | 57 | 138 | 0 |
| 31 Dec 22 | 487 | 47 | 130 | 0 |
| 30 Sep 22 | 454 | 36 | 122 | 0 |
| 30 Jun 22 | 430 | 30 | 122 | 0 |
| 31 Mar 22 | 406 | 25 | 123 | 0 |
| 31 Dec 21 | 398 | 18 | 124 | 0 |
| 30 Sep 21 | 390 | 11 | 126 | 0 |
| 30 Jun 21 | 394 | 17 | 127 | 0 |
| 31 Mar 21 | 397 | 23 | 128 | 0 |
| 31 Mar 20 | 382 | 41 | 139 | 0 |
| 31 Mar 19 | 308 | 52 | 107 | 0 |
| 31 Mar 18 | 264 | 42 | 95 | 0 |
Kwaliteitswinsten: 2161 has high quality earnings.
Groeiende winstmarge: 2161's current net profit margins (20.1%) are higher than last year (11%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: 2161's earnings have grown significantly by 32.3% per year over the past 5 years.
Versnelling van de groei: 2161's earnings growth over the past year (128.5%) exceeds its 5-year average (32.3% per year).
Winst versus industrie: 2161 earnings growth over the past year (128.5%) exceeded the Pharmaceuticals industry 6.4%.
Rendement op eigen vermogen
Hoge ROE: 2161's Return on Equity (13.4%) is considered low.